A variety of myositis‐specific autoantibodies have been identified in sera from patients with idiopathic inflammatory myopathies, and they play a crucial role in tailoring personalized disease management. In particular, autoantibodies… Click to show full abstract
A variety of myositis‐specific autoantibodies have been identified in sera from patients with idiopathic inflammatory myopathies, and they play a crucial role in tailoring personalized disease management. In particular, autoantibodies against 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR) are now recognized as a key tool for diagnosing immune‐mediated necrotizing myopathy. The current gold standard for detecting anti‐HMGCR autoantibodies involves immunoprecipitation (IP) using radiolabeled proteins from cell extracts or purified proteins produced by in vitro transcription/translation (IVTT). Unfortunately, this radioisotope labeling is technically intricate and not suitable for routine laboratory use. To address this, we developed a novel assay called “Bio‐IVTT‐IP” for detecting anti‐HMGCR autoantibodies, which uses a nonradioactive biotinylated recombinant HMGCR protein produced by IVTT.
Journal Title: Clinical and Experimental Neuroimmunology
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!